Rapport Therapeutics, Inc. 4

CEO Abraham Ceesay sold 8,210 shares of Rapport Therapeutics, Inc. common stock on July 14, 2026, for about $0.33 million under a Rule 10b5-1 plan.

On July 14, 2026, Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay sold a total of 8,210 shares of the company’s common stock in two open-market transactions effected under a Rule 10b5-1 trading plan adopted on March 27, 2026, at weighted average prices of $39.7217 and $40.5724 per share, for aggregate proceeds of roughly $325,000. Following these sales, he directly owns 539,817 shares of common stock, and there are additional indirect holdings of 81,729 shares in the Ceesay Family Irrevocable Trust and 20,729 shares in the Dorothy Ceesay Irrevocable Trust, for which he disclaims beneficial ownership except to the extent of any pecuniary interest. The prices reported are weighted averages for multiple trades within tight intraday ranges, and the transactions appear to be orderly, preplanned sales rather than opportunistic disposals.

Filing Facts

CIK

2012593

Ticker

RAPP

Form

4

Source Type

fda

Accession

0001193125-26-304786

Alert Tier

6